Legal status · United States
Is Navepegritide legal in the United States?
Yes. Navepegritide is an approved medicine in the United States, classified as "FDA-approved (achondroplasia), prescription only". Approval covers its labeled indication and it is supplied on prescription, not over the counter. Products labeled "research use only" fall outside that approval and the label does not make human use lawful. Human evidence: Strong.
Navepegritide in the United States at a glance
| Classification | FDA-approved (achondroplasia), prescription only |
|---|---|
| FDA approval status | FDA-approved (accelerated) for achondroplasia, 2026 |
| Evidence level | Strong (research strength: Strong) |
| Reviewed | Sep 2026 |
Classification and note come from the Navepegritide profile, checked against U.S. Food and Drug Administration (FDA) listings at the reviewed date.
What this means
- 01
FDA has approved Navepegritide for at least one labeled indication, so a pharmaceutical-grade product exists in the United States and is dispensed on prescription.
- 02
Approval is indication-specific. Uses outside the label are a clinical decision for a prescriber, not something the approval itself authorizes.
- 03
Unlicensed online vials, including those labeled "research use only", are not the approved product and are not covered by the approval.
What Navepegritide is
A once-weekly prodrug of C-type natriuretic peptide, FDA-approved in February 2026 for achondroplasia in children aged two and older.
Navepegritide releases C-type natriuretic peptide slowly from a carrier, giving a weekly injection that counters the overactive FGFR3 signaling of achondroplasia. 41 on placebo.
Mechanism: Sustained-release CNP analog that stimulates natriuretic peptide receptor B, inhibiting the MAPK pathway downstream of FGFR3 in growth-plate cartilage.
Regulatory history: FDA-approved (accelerated) for achondroplasia, 2026
How FDA treats this kind of product
Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.
The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for Navepegritide at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
Navepegritide in other countries
Frequently asked questions
Is Navepegritide legal in the United States?
Yes. Navepegritide is an approved medicine in the United States, classified as "FDA-approved (achondroplasia), prescription only". Approval covers its labeled indication and it is supplied on prescription, not over the counter. Products labeled "research use only" fall outside that approval and the label does not make human use lawful. Human evidence: Strong.
Can I buy Navepegritide in the United States?
Only with a prescription. Navepegritide is classified as "FDA-approved (achondroplasia), prescription only" in the United States, so it is dispensed by pharmacies against a prescription for its approved indication. Buying it from unlicensed online sellers or as a "research chemical" is outside that system and carries no regulatory protection.
Is Navepegritide FDA approved?
Yes. FDA status: FDA-approved (accelerated) for achondroplasia, 2026. Current US classification: "FDA-approved (achondroplasia), prescription only". Evidence level: Strong.
Related compounds in the United States
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for Navepegritide live on its compound profile.
Navepegritide profileThis page is general information about the regulatory status of Navepegritide in the United States, current as of Sep 2026. It is not legal advice, and classifications change; check U.S. Food and Drug Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.